Who Is Buying Eli Lilly? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Eli Lilly (LLY) stock based on the latest SEC 13F filings. Complete institutional ownership breakdown.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Eli Lilly? Hedge Fund Activity in 2026
Eli Lilly has become the most valuable pharmaceutical company in the world, driven by the GLP-1 revolution in obesity and diabetes treatment. With blockbuster drugs Mounjaro and Zepbound generating tens of billions in revenue, LLY has attracted massive institutional interest. But the latest 13F data reveals a nuanced picture — not every fund is adding.
In this analysis, we examine which hedge funds are buying, selling, and holding Eli Lilly based on the latest SEC 13F filings and what their moves signal about the pharma giant's future.
Quick Answer
Across the funds we read directly from SEC filings, the largest Eli Lilly position in the Q2 2026 13Fs (period ending 30 June 2026) is Citadel Advisors at $1.13B (945,456 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Citadel Advisors, where Eli Lilly is 0.7% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Eli Lilly at a Glance
| Metric | Value |
|---|---|
| Ticker | LLY |
| Sector | Healthcare — Pharmaceuticals |
| Share Price | $935.6 |
| Market Cap | ~$890 billion |
| Institutional Ownership | ~78% of float |
| Number of 13F Holders | 4,800+ |
Who holds Eli Lilly, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Citadel Advisors | $1.13B | 945,456 | 0.7% of $171.84B |
| Millennium Management | $219M | 182,678 | 0.2% of $142.92B |
| Bridgewater Associates | $104M | 87,023 | 0.4% of $24.38B |
| Renaissance Technologies | $31M | 26,091 | 0.0% of $72.62B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Eli Lilly that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Who added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Citadel Advisors | 241,714 | 945,456 | +291% |
| Renaissance Technologies | 71,788 | 26,091 | -64% |
| Millennium Management | 275,989 | 182,678 | -34% |
| Bridgewater Associates | 70,812 | 87,023 | +23% |
A fund absent from this table reported no Eli Lilly position in either quarter.
What Eli Lilly's Institutional Activity Signals
The GLP-1 Mega-Trend Is Priced In — But Growth Continues
Eli Lilly's GLP-1 drugs (Mounjaro for diabetes, Zepbound for obesity) have generated a combined $30+ billion in annual revenue and are still growing at 40%+ year-over-year. However, the stock's premium valuation means much of this growth is already reflected in the share price. The institutional split — some funds adding, others trimming — reflects the tension between exceptional fundamentals and a demanding valuation.
Competition Is Coming
Novo Nordisk (Ozempic, Wegovy) remains the primary competitor, but dozens of companies are developing next-generation GLP-1 drugs, including oral formulations and combination therapies. Funds trimming LLY may be anticipating margin and pricing pressure as the obesity drug market becomes more competitive by 2027-2028.
Pipeline Beyond GLP-1
Institutional bulls point to Eli Lilly's pipeline beyond obesity and diabetes: Alzheimer's treatment donanemab, oncology candidates, and immunology drugs provide diversification. However, GLP-1 drugs represent such a massive share of the company's value that the pipeline optionality is secondary for most investors.
The Citadel Divergence
Citadel's 3.9% decrease in LLY, contrasted with its 244.95% increase in UnitedHealth, suggests a potential intra-healthcare rotation — moving from high-multiple pharma to healthcare services with more predictable growth. This type of sector rotation within healthcare is a pattern worth monitoring across other funds as well.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeSector Context: Pharma and the Obesity Revolution
Eli Lilly operates at the center of what many call the biggest pharmaceutical opportunity since statins:
- The global obesity drug market is projected to reach $150 billion by 2030, up from virtually zero in 2020
- Eli Lilly and Novo Nordisk currently control approximately 90% of the GLP-1 market
- Insurance coverage expansion for obesity treatments is accelerating, with Medicare coverage under active legislative discussion
- Next-generation compounds (oral pills, muscle-sparing formulations) could expand the market dramatically
- Competition from Amgen, Pfizer, Roche, and others is 2-3 years behind Lilly and Novo
For hedge funds, Eli Lilly represents either a generational growth story or a crowded trade at peak valuation — and the 13F data shows both views are well-represented among top institutions.
How to Track Eli Lilly Institutional Activity with Freenance
Freenance's Smart Money feature helps you navigate the nuanced institutional picture for LLY:
- Tracks 35 major hedge funds with a combined $21.4T in total AUM and 77,111 positions
- See Citadel's $2.4B LLY position — 2.2M shares with the -3.9% decrease highlighted
- Compare buying vs selling across all tracked funds to gauge whether accumulation or distribution dominates
- Track healthcare sector rotation — see if funds are shifting between pharma (LLY) and managed care (UNH)
Understanding the nuances of institutional positioning — like Citadel's simultaneous LLY trim and UNH accumulation — requires the kind of cross-fund analysis that Freenance Smart Money makes effortless.
👉 Track LLY institutional moves in real-time with Freenance Smart Money — Try it free
Frequently Asked Questions (Original)
How many hedge funds own Eli Lilly?
Over 4,800 institutional investors report holding Eli Lilly in their Q4 2025 13F filings. Among hedge funds specifically, approximately 1,000+ hold LLY positions, making it the most widely held pharmaceutical stock in institutional portfolios.
Is Citadel selling Eli Lilly?
Citadel reduced its Eli Lilly position by 3.9% to $2.4 billion (2.2 million shares) in Q4 2025. This is a modest trim rather than a sell signal — Citadel still holds a multi-billion dollar position. The reduction may reflect portfolio rebalancing or rotation toward other healthcare opportunities like UnitedHealth.
Is Eli Lilly overvalued?
At approximately 50x forward earnings, Eli Lilly trades at a significant premium to both the pharmaceutical sector and the broader market. Bulls argue the GLP-1 revenue trajectory justifies the premium. Bears point to eventual competition and the risk of pricing pressure. The institutional data shows credible arguments on both sides.
Should I buy Eli Lilly because hedge funds are buying it?
The institutional picture for LLY is mixed — some major funds are adding while others are trimming. This makes independent analysis especially important. Use Freenance Smart Money to understand the full institutional landscape, but base your decisions on your own research into Eli Lilly's fundamentals, competitive position, and your risk tolerance.
FAQ
Where can I find the raw 13F data for Eli Lilly?
The authoritative source is SEC EDGAR (sec.gov/edgar) — every institutional manager with over $100M in US equity AUM must file Form 13F-HR each quarter listing long positions including LLY. Aggregators reformat this data for easier browsing, but EDGAR is the underlying public source for institutional holdings in Eli Lilly.
Why is the Eli Lilly hedge fund data already 45 days old when published?
The SEC grants filers 45 calendar days after each quarter-end to submit their 13F report. Q4 2025 LLY positions therefore only became visible around mid-February 2026, and a fund's holding today may differ substantially. 13F data is a snapshot of the past, not a live portfolio feed.
Is copying hedge funds into Eli Lilly a sound strategy?
Mirroring 13F filings has notable limits — you only see long US equities, with no view of shorts, options, or hedges, and you see them with a lag. Funds operate with leverage, tax structures, and time horizons retail investors do not share. Treat institutional flows as one data point among many, not a trade trigger.
What does institutional buying of LLY signal vs retail flows?
With ~78% of float held by institutions, large-fund positioning typically drives the medium-term path of LLY's price. Retail demand affects short-term volatility but rarely changes the longer-term trajectory of a stock this widely owned. The split picture in Q4 2025 — some funds adding, others trimming — actually reduces the signal strength here.
How are Eli Lilly stock returns taxed in Poland?
Polish residents pay the 19% Belka tax on both dividends and capital gains from US-listed LLY. Submitting form W-8BEN to your broker drops US dividend withholding from 30% to 15% under the US–Poland treaty; the remaining 4% is settled via your annual PIT-38. Treaty terms can change, so verify with a Polish tax advisor.